JMP Securities analyst Silvan Tuerkcan initiated coverage of enGene (ENGN) with an Outperform rating and $18 price target enGene is a clinical-stage biotechnology company focused on developing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback